Reported 2 days ago
Jim Cramer expressed skepticism about Arrowhead Pharmaceuticals (NASDAQ:ARWR), stating that the company 'doesn’t make any money' and questioning its future potential. Despite its focus on RNA-based treatments for various diseases, Cramer remains cautious, emphasizing that while he appreciates biotechnology, he views ARWR mainly as a speculative investment, especially given its stock decline of over 75% since his previous comments.
Source: YAHOO